Valuation: Serina Therapeutics, Inc.

Market Cap 28.5M 24.91M 22.89M 21.34M 40.47M 2.71B 41.09M 275M 107M 1.33B 107M 105M 4.6B P/E 2026 *
-0.97x
P/E 2027 * -1.21x
Enterprise Value 28.5M 24.91M 22.89M 21.34M 40.47M 2.71B 41.09M 275M 107M 1.33B 107M 105M 4.6B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
14.04%
Yield 2026 *
-
Yield 2027 * -
1 day-1.04%
1 week+4.40%
Current month-2.06%
1 month+7.95%
3 months-10.38%
6 months-8.57%
Current year-0.68%
1 week 1.84
Extreme 1.84
2.01
1 month 1.71
Extreme 1.71
2.18
Current year 1.22
Extreme 1.22
4.08
1 year 1.22
Extreme 1.22
7.92
3 years 1.22
Extreme 1.22
19.93
5 years 1.22
Extreme 1.22
19.93
10 years 1.22
Extreme 1.22
19.93
Date Insider Type Main position Quantity % Market Cap.
06-17Conversion

Director

239,402 1.5963%
06-17Conversion

Director

-96,525 1.9305%
06-17Other

Director

15,250 0.1017%
Change 5-day change 1-year change 3-year change Capi.($)
-1.04%+4.40%-69.06% - 28.5M
+0.68%+6.27%+77.60%+133.76% 58.73B
+2.32%+5.89%+76.81%+99.20% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.47%+46.43%+0.03% 18.8B
-0.29%+8.57%+44.17%-27.58% 17.61B
0.00%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+20.94%+51.67% - 13.9B
Average +2.48%+6.89%+42.85%+146.62% 24.21B
Weighted average by Cap. +2.44%+5.53%+59.05%+137.34%

Financials

2026 *2027 *
Net sales - -
Net income -26.61M -23.26M -21.38M -19.93M -37.8M -2.53B -38.37M -257M -99.78M -1.25B -99.89M -97.75M -4.29B -27.18M -23.76M -21.84M -20.35M -38.61M -2.59B -39.19M -262M -102M -1.27B -102M -99.83M -4.38B
Net Debt - -
Logo Serina Therapeutics, Inc.
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
Employees
16
Date Price Change Volume
02/07/26 $1.900 -1.04% 19,117
01/07/26 $1.920 -1.03% 73,263
30/06/26 $1.940 -1.52% 40,385
29/06/26 $1.970 +8.84% 59,477
26/06/26 $1.810 -0.55% 77,006
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.900USD
Average target price
9.500USD
Spread / Average Target
+400.00%

Quarterly revenue - Rate of surprise